Dr. Sangro on the Efficacy of Nivolumab in HCC

Bruno Sangro, MD, PhD
Published: Tuesday, Jun 27, 2017



Bruno Sangro, MD, PhD head of Hepatology Unit, Internal Medicine Department, Clínica Universidad de Navarra, discusses the efficacy of nivolumab (Opdivo) in patients with hepatocellular carcinoma (HCC).

Usually in phase Ib/II trials, efficacy is not observed. However, in this trial investigating nivolumab, there was clinically relevant anti-tumor activity, explains Sangro.

According to Sangro, the response rate was between 15% to 20%, the median duration of response was 17 months, and a portion of patients had prolonged stable disease.



Bruno Sangro, MD, PhD head of Hepatology Unit, Internal Medicine Department, Clínica Universidad de Navarra, discusses the efficacy of nivolumab (Opdivo) in patients with hepatocellular carcinoma (HCC).

Usually in phase Ib/II trials, efficacy is not observed. However, in this trial investigating nivolumab, there was clinically relevant anti-tumor activity, explains Sangro.

According to Sangro, the response rate was between 15% to 20%, the median duration of response was 17 months, and a portion of patients had prolonged stable disease.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x